Alnylam Pharmaceuticals has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, to investigate the molecular mechanisms of small interfering RNA (siRNA), the molecules that mediate RNAi.     Alnylam scientists will work with the lab of Marino Zerial, Ph.D., a team that specializes in intracellular trafficking, to investigate cellular uptake pathways in a high-throughput manner. Alnylam will have an option on any inte...